Imcyse is a clinical-stage biopharmaceutical company committed to transforming the treatment of severe, chronic autoimmune diseases. With a focus on severe autoimmune conditions, they are pioneering the development of a new class of antigen-specific immunotherapies. Using their unique ImotopeTM technology platform, Imcyse aims to make a meaningful impact on a wide range of indications in the field of autoimmunity and other diseases where the immune system breaks down.

Imcyse's revolutionary approach focuses on inducing a special type of T cell called cytolytic CD4+ T cell, which can effectively control the inflammatory processes and autoimmune attacks that lead to severe autoimmune diseases. Unlike current therapies that suppress the entire immune system, Imcyse's synthetic peptides, known as ImotopesTM, selectively target and delete only the cells responsible for driving the disease. Through their groundbreaking research, Imcyse is on a journey to provide potential cures for some of the most challenging and underserved areas of modern medicine.

If successful, their technology has the potential to stop disease progression and bring hope to patients suffering from autoimmune diseases